… IIb/III CLEVER trial (NCT04767373) evaluating a single … Treatment with Enflonsia reduced the incidence of RSV-associated medically attended … of Sobi’s Synagis (palivizumab), an older mAb which … to become a successful drug in the pediatric market, …

… US Food and Drug Administration (FDA) has approved Enflonsia … (MK-1654-007) trials. “Enflonsia combines dosing … with RSV-associated medically attended lower respiratory infection … partially-blind, palivizumab-controlled, multi-site trial to evaluate the …

… -associated medically attended lower respiratory infection were comparable to palivizumab. “ … on the CLEVER and SMART trials., said in a release … phase 2b/3 trial that evaluated the efficacy … newsletter and get the latest drug information, industry trends, …

… incidence of RSV-associated medically attended lower respiratory infections … and rash, with no treatment-related deaths reported. “RSV … CLEVER and SMART (NCT04938830) trials, said in a statement. … and compared clesrovimab against palivizumab.4 Rates of RSV- …

… FDA based its approval on data from 2 key phase 3 trials … trial (N = 3,614), clesrovimab reduced the incidence of RSV-associated medically … phase 3 SMART trial (N=896) compared clesrovimab to palivizumab in high …

… Healio Key takeaways: The FDA approved the monoclonal antibody … brand name Enflonsia. The FDA approved clesrovimab for the … trial in which one dose of clesrovimab reduced RSV-associated medically … compared with five doses of palivizumab — an mAb that has …

… U.S. Food and Drug Administration (FDA) has approved ENFLONSIA™ … (MK-1654-007) trials. “ENFLONSIA combines dosing convenience … incidence of RSV-associated medically attended lower respiratory infections … efficacy of ENFLONSIA versus palivizumab in infants at …

… the US Food and Drug Administration (FDA) for use in … incidence of RSV-associated medically attended lower respiratory infections … phase 3 SMART trial comparing Enflonsia against palivizumab, another RSV … the CLEVER and SMART trials. The US Centers for …

… US Food and Drug Administration (FDA) approval for … efficacy in reducing medically attended lower respiratory … trial, in which Enflonsia’s safety profile was assessed against palivizumab … for the prestigious Pharmaceutical Technology Excellence Awards …

The US Food and Drug Administration (FDA) has approved Merck’s clesrovimab ( … treatment demonstrated strong efficacy in pivotal Phase 2b/3 trials,reducing medically … ongoing Phase 3 SMART trial, comparing enflonsia to palivizumab in infants at …